Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2024(Status and Outlook)
Report Overview:
Pegfilgrastim, sold under the brand nameNeulastaamong others, is aPEGylatedform of the recombinant humangranulocyte colony-stimulating factor(GCSF) analogfilgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed byAmgen.
The Global Neulasta (Pegfilgrastim) and Biosimilar Market Size was estimated at USD 2591.40 million in 2023 and is projected to reach USD 3781.22 million by 2029, exhibiting a CAGR of 6.50% during the forecast period.
This report provides a deep insight into the global Neulasta (Pegfilgrastim) and Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neulasta (Pegfilgrastim) and Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neulasta (Pegfilgrastim) and Biosimilar market in any manner.
Global Neulasta (Pegfilgrastim) and Biosimilar Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market Segmentation (by Type)
Brand
Biosimilar
Market Segmentation (by Application)
Hospital
Pharmacy
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neulasta (Pegfilgrastim) and Biosimilar Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Pegfilgrastim, sold under the brand nameNeulastaamong others, is aPEGylatedform of the recombinant humangranulocyte colony-stimulating factor(GCSF) analogfilgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed byAmgen.
The Global Neulasta (Pegfilgrastim) and Biosimilar Market Size was estimated at USD 2591.40 million in 2023 and is projected to reach USD 3781.22 million by 2029, exhibiting a CAGR of 6.50% during the forecast period.
This report provides a deep insight into the global Neulasta (Pegfilgrastim) and Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neulasta (Pegfilgrastim) and Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neulasta (Pegfilgrastim) and Biosimilar market in any manner.
Global Neulasta (Pegfilgrastim) and Biosimilar Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market Segmentation (by Type)
Brand
Biosimilar
Market Segmentation (by Application)
Hospital
Pharmacy
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neulasta (Pegfilgrastim) and Biosimilar Market
- Overview of the regional outlook of the Neulasta (Pegfilgrastim) and Biosimilar Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neulasta (Pegfilgrastim) and Biosimilar Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Key Market Segments
1.2.1 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET COMPETITIVE LANDSCAPE
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Manufacturers (2019-2024)
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2019-2024)
3.3 Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Sales Sites, Area Served, Product Type
3.6 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
3.6.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR INDUSTRY CHAIN ANALYSIS
4.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2019-2024)
6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Market Share by Type (2019-2024)
6.4 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2019-2024)
7 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Sales by Application (2019-2024)
7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Application (2019-2024)
7.4 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
8 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY REGION
8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region
8.2 North America
8.2.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Amgen
9.1.1 Amgen Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.1.4 Amgen Business Overview
9.1.5 Amgen Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.1.6 Amgen Recent Developments
9.2 Viatris
9.2.1 Viatris Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.2.4 Viatris Business Overview
9.2.5 Viatris Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.2.6 Viatris Recent Developments
9.3 Coherus
9.3.1 Coherus Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.3.5 Coherus Business Overview
9.3.6 Coherus Recent Developments
9.4 Novartis
9.4.1 Novartis Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.4.4 Novartis Business Overview
9.4.5 Novartis Recent Developments
9.5 Pfizer
9.5.1 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 Amneal Pharmaceutical
9.6.1 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.6.4 Amneal Pharmaceutical Business Overview
9.6.5 Amneal Pharmaceutical Recent Developments
9.7 Fresenius Kabi
9.7.1 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.7.4 Fresenius Kabi Business Overview
9.7.5 Fresenius Kabi Recent Developments
10 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET FORECAST BY REGION
10.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast
10.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
10.2.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
10.2.4 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neulasta (Pegfilgrastim) and Biosimilar by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Type (2025-2030)
11.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neulasta (Pegfilgrastim) and Biosimilar by Type (2025-2030)
11.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Application (2025-2030)
11.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) Forecast by Application
11.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Key Market Segments
1.2.1 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET COMPETITIVE LANDSCAPE
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Manufacturers (2019-2024)
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2019-2024)
3.3 Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Sales Sites, Area Served, Product Type
3.6 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
3.6.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR INDUSTRY CHAIN ANALYSIS
4.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2019-2024)
6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Market Share by Type (2019-2024)
6.4 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2019-2024)
7 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Sales by Application (2019-2024)
7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Application (2019-2024)
7.4 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
8 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY REGION
8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region
8.2 North America
8.2.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Amgen
9.1.1 Amgen Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.1.4 Amgen Business Overview
9.1.5 Amgen Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.1.6 Amgen Recent Developments
9.2 Viatris
9.2.1 Viatris Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.2.4 Viatris Business Overview
9.2.5 Viatris Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.2.6 Viatris Recent Developments
9.3 Coherus
9.3.1 Coherus Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
9.3.5 Coherus Business Overview
9.3.6 Coherus Recent Developments
9.4 Novartis
9.4.1 Novartis Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.4.4 Novartis Business Overview
9.4.5 Novartis Recent Developments
9.5 Pfizer
9.5.1 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 Amneal Pharmaceutical
9.6.1 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.6.4 Amneal Pharmaceutical Business Overview
9.6.5 Amneal Pharmaceutical Recent Developments
9.7 Fresenius Kabi
9.7.1 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Basic Information
9.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
9.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
9.7.4 Fresenius Kabi Business Overview
9.7.5 Fresenius Kabi Recent Developments
10 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET FORECAST BY REGION
10.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast
10.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
10.2.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
10.2.4 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neulasta (Pegfilgrastim) and Biosimilar by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Type (2025-2030)
11.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neulasta (Pegfilgrastim) and Biosimilar by Type (2025-2030)
11.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Application (2025-2030)
11.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) Forecast by Application
11.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neulasta (Pegfilgrastim) and Biosimilar Market Size Comparison by Region (M USD)
Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2022)
Table 10. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Sales Sites and Area Served
Table 12. Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Product Type
Table 13. Global Neulasta (Pegfilgrastim) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neulasta (Pegfilgrastim) and Biosimilar
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
Table 22. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (Kilotons)
Table 23. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2019-2024)
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Type (2019-2024)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Share by Type (2019-2024)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Application
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2019-2024)
Table 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2019-2024) & (M USD)
Table 34. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2019-2024)
Table 35. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
Table 36. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2019-2024)
Table 38. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 43. Amgen Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 44. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 45. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Amgen Business Overview
Table 47. Amgen Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 48. Amgen Recent Developments
Table 49. Viatris Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 50. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 51. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Viatris Business Overview
Table 53. Viatris Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 54. Viatris Recent Developments
Table 55. Coherus Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 56. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 57. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Coherus Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 59. Coherus Business Overview
Table 60. Coherus Recent Developments
Table 61. Novartis Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 62. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 63. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Novartis Business Overview
Table 65. Novartis Recent Developments
Table 66. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 67. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 68. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 72. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 73. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Amneal Pharmaceutical Business Overview
Table 75. Amneal Pharmaceutical Recent Developments
Table 76. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 77. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 78. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Fresenius Kabi Business Overview
Table 80. Fresenius Kabi Recent Developments
Table 81. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2025-2030) & (Kilotons)
Table 82. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2025-2030) & (M USD)
Table 83. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 84. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 85. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 86. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 87. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2025-2030) & (Kilotons)
Table 88. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2025-2030) & (M USD)
Table 89. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 90. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 91. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Country (2025-2030) & (Units)
Table 92. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 93. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2025-2030) & (Kilotons)
Table 94. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2025-2030) & (M USD)
Table 95. Global Neulasta (Pegfilgrastim) and Biosimilar Price Forecast by Type (2025-2030) & (USD/Ton)
Table 96. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) Forecast by Application (2025-2030)
Table 97. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neulasta (Pegfilgrastim) and Biosimilar Market Size Comparison by Region (M USD)
Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2022)
Table 10. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Sales Sites and Area Served
Table 12. Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Product Type
Table 13. Global Neulasta (Pegfilgrastim) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neulasta (Pegfilgrastim) and Biosimilar
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
Table 22. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (Kilotons)
Table 23. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2019-2024)
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Type (2019-2024)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Share by Type (2019-2024)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) by Application
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2019-2024)
Table 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2019-2024) & (M USD)
Table 34. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2019-2024)
Table 35. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
Table 36. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2019-2024)
Table 38. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2019-2024) & (Kilotons)
Table 43. Amgen Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 44. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 45. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Amgen Business Overview
Table 47. Amgen Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 48. Amgen Recent Developments
Table 49. Viatris Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 50. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 51. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Viatris Business Overview
Table 53. Viatris Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 54. Viatris Recent Developments
Table 55. Coherus Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 56. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 57. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Coherus Neulasta (Pegfilgrastim) and Biosimilar SWOT Analysis
Table 59. Coherus Business Overview
Table 60. Coherus Recent Developments
Table 61. Novartis Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 62. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 63. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Novartis Business Overview
Table 65. Novartis Recent Developments
Table 66. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 67. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 68. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Pfizer Business Overview
Table 70. Pfizer Recent Developments
Table 71. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 72. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 73. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Amneal Pharmaceutical Business Overview
Table 75. Amneal Pharmaceutical Recent Developments
Table 76. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Basic Information
Table 77. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 78. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Fresenius Kabi Business Overview
Table 80. Fresenius Kabi Recent Developments
Table 81. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2025-2030) & (Kilotons)
Table 82. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2025-2030) & (M USD)
Table 83. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 84. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 85. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 86. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 87. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2025-2030) & (Kilotons)
Table 88. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2025-2030) & (M USD)
Table 89. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2025-2030) & (Kilotons)
Table 90. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 91. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Country (2025-2030) & (Units)
Table 92. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2025-2030) & (M USD)
Table 93. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2025-2030) & (Kilotons)
Table 94. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2025-2030) & (M USD)
Table 95. Global Neulasta (Pegfilgrastim) and Biosimilar Price Forecast by Type (2025-2030) & (USD/Ton)
Table 96. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) Forecast by Application (2025-2030)
Table 97. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD), 2019-2030
Figure 5. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) (2019-2030)
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (M USD)
Figure 11. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2023
Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2023
Figure 13. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neulasta (Pegfilgrastim) and Biosimilar Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type
Figure 18. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2019-2024)
Figure 19. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2023
Figure 20. Market Size Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2019-2024)
Figure 21. Market Size Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application
Figure 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2019-2024)
Figure 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application in 2023
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2019-2024)
Figure 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2023
Figure 28. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2019-2024)
Figure 30. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 32. U.S. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neulasta (Pegfilgrastim) and Biosimilar Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 37. Germany Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2023
Figure 44. China Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 50. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 51. Brazil Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Type (2025-2030)
Figure 65. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2025-2030)
Figure 66. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD), 2019-2030
Figure 5. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) (2019-2030)
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (M USD)
Figure 11. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2023
Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2023
Figure 13. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neulasta (Pegfilgrastim) and Biosimilar Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type
Figure 18. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2019-2024)
Figure 19. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2023
Figure 20. Market Size Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2019-2024)
Figure 21. Market Size Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application
Figure 24. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2019-2024)
Figure 25. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application in 2023
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2019-2024)
Figure 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2023
Figure 28. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2019-2024)
Figure 30. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 32. U.S. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neulasta (Pegfilgrastim) and Biosimilar Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neulasta (Pegfilgrastim) and Biosimilar Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 37. Germany Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2023
Figure 44. China Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 50. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2023
Figure 51. Brazil Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Type (2025-2030)
Figure 65. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2025-2030)
Figure 66. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Application (2025-2030)
